VRTX · News · 20260930N
Revenue Performance and Mix
VERTEX PHARMACEUTICALS INC / MA · 2026-09-30 · Importance 33 · Surprise 6 · In source text
Vertex Pharmaceuticals reported Q2 2026 revenue of USD 3.33 billion. The third-party report characterized the quarterly revenue performance as strong. The report provided no year-over-year, sequential, segment, or geographic revenue breakdown.
Key facts
- Vertex reported strong Q2 2026 revenue of USD 3.33 billion. source
- UBS has raised its price target for Vertex Pharmaceuticals to USD 615.00 from USD 585.00 and maintained a Buy rating. source
- Vertex Pharmaceuticals (VRTX) stock was trading at EUR 464.53, up 0.02% at Lang & Schwarz. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | — | Vertex reported strong Q2 2026 revenue of USD 3.33 billion. |